Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001388325-25-000011·4D Molecular Therapeutics, Inc.
Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 35104E100
Event date: 2025-10-13
- Filing-level shares
- 3,175,000.00
- Percent of class
- 6.8%
- Novo Holdings A/S
Shares: 3,175,000.00 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001388325-25-000011
- Form type
- SCHEDULE 13G
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Oct 20, 2025
- Reporting period
- Oct 13, 2025
- Description
- Schedule 13G beneficial ownership